Clinical Updatesacute myeloid leukaemiahematopoietic stem-cell transplantation
Oral Decitabine and Cedazuridine Maintenance Post-HSCT: Promising Strategy in High-Risk AML and MDS
By MedXY|Oct 9, 2025
A phase 2 trial demonstrates that oral hypomethylating agent ASTX727, with optional donor lymphocyte infusion, shows encouraging disease-free survival and manageable safety after stem-cell transplantation in very high-risk acute myeloid leu
